WO2016065930A1 - Crystal forms of verapamil hydrochloride - Google Patents
Crystal forms of verapamil hydrochloride Download PDFInfo
- Publication number
- WO2016065930A1 WO2016065930A1 PCT/CN2015/083854 CN2015083854W WO2016065930A1 WO 2016065930 A1 WO2016065930 A1 WO 2016065930A1 CN 2015083854 W CN2015083854 W CN 2015083854W WO 2016065930 A1 WO2016065930 A1 WO 2016065930A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- crystalline
- verapamil hydrochloride
- powder
- ray diffraction
- crystal
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
- C07C255/43—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C253/00—Preparation of carboxylic acid nitriles
- C07C253/32—Separation; Purification; Stabilisation; Use of additives
- C07C253/34—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- the present disclosure relates to novel crystalline forms of (R) - (+) Verapamil hydrochloride.
- Verapamil HCl e.g., 2- (3, 4-dimethoxyphenyl) -5- [2- (3, 4-dimethoxyphenyl) ethyl-methylamino] -2-propa n-2-ylpentanenitrile
- 2- (3, 4-dimethoxyphenyl) -5- [2- (3, 4-dimethoxyphenyl) ethyl-methylamino] -2-propa n-2-ylpentanenitrile is a known drug with various medicinal indications. Traditionally, it is used for treating coronary disease, such as hypertension. The compound has a stereogenic center, hence can be separated into its optical enantiomers.
- the (S) -enantiomer is known to possess the majority of the calcium channel antagonist activity, whereas the (R) -enantiomer is known to possess agonist activity toward somatostatin receptor 2, and antagonist activity toward orexin receptors 1 and 2, dopamine D 2L receptor, sodium and calcium channels; accordingly, the (R) -enantiomer is useful as a medicament for treating diseases or conditions related to these receptors in a human subject. Therefore, single isomer products may offer clinical utility on medical conditions related to those receptors and/or ion channels.
- the object of the present disclosure is to provide novel crystals of (R) - (+) verapamil hydrochloride. After intensive studies, form E and form T crystals of (R) - (+) verapamil hydrochloride are obtained. Each crystals has improved storage stability, solubility and/or purity, and is easier to process under typical pharmaceutical processing conditions such as wet granulation, thus the (R) - (+) verapamil hydrochloride crystalline of the present disclosure is suitable for use as a drug substance or an active compound of a pharmaceutical composition.
- the powder X-ray diffraction pattern of form E crystalline of (R) - (+) verapamil hydrochloride further comprises characteristic peaks of 6.4° ⁇ 0.1°, 8.3° ⁇ 0.1°, 10.7° ⁇ 0.1°, 15.5° ⁇ 0.1°, 15.9° ⁇ 0.1°, 17.5° ⁇ 0.1°, 20.4° ⁇ 0.1°, 23.9° ⁇ 0.1°, 24.4° ⁇ 0.1°, 25.4° ⁇ 0.1°, 25.9° ⁇ 0.1°, 27.7° ⁇ 0.1°, 27.0° ⁇ 0.1°, and 29.8° ⁇ 0.1°at reflection angles 2 ⁇ . Specifically, it yields a powder X-ray diffraction pattern as depicted in FIG 2.
- the form E crystalline as measured by differential scanning calorimetry (DSC) , exhibits an endothermic peak at about 139 ⁇ 0.1°C. Further, it has a water content of about 0% (wt%) at 3%relative humidity (RH) , and a water content of about 21% (wt%) at 95%RH.
- the second aspect of the present disclosure is to provide a form T crystal of (R) - (+) verapamil hydrochloride, which yields a powder X-ray diffraction pattern comprising characteristic peaks of 8.5° ⁇ 0.1°, 9.5° ⁇ 0.1°, 17.6° ⁇ 0.1°, 21.4° ⁇ 0.1°, and 22.3° ⁇ 0.1°at reflection angles 2 ⁇ .
- the powder X-ray diffraction pattern of form T crystalline of (R) - (+) verapamil hydrochloride further comprises characteristic peaks of 5.4° ⁇ 0.1°, 9.6° ⁇ 0.1°, 15.7° ⁇ 0.1°, 17.1° ⁇ 0.1°, 21.5° ⁇ 0.1°, 21.6° ⁇ 0.1°, 23.3° ⁇ 0.1°, 24.6° ⁇ 0.1°and 25.5° ⁇ 0.1°at reflection angles 2 ⁇ . Specifically, it yields a powder X-ray diffraction pattern as depicted in FIG 3.
- each crystals of (R) - (+) verapamil hydrochloride is substantially pure, with a level of individual impurity that is less than 1.0%; preferably, less than 0.5%; and most preferably, less than 0.1%.
- the form E or T crystalline of (R) - (+) verapamil hydrochloride is suitable for use as a drug substance for manufacturing a medicament.
- the medicament is suitable for treating diseases or conditions related to orexin receptor 1, orexin receptor 2, somatostatin receptor 2, dopamine D 2L receptor, sodium channel or L-and N-type calcium channels in a subject.
- the third aspect of the present disclosure is directed to a method of making a crystalline of (R) - (+) -verapamil hydrochloride, which comprises steps of, dissolving (R) - (+) -verapamil hydrochloride in the least amount of a solvent to form a solution; cooling the solution; and collecting an amount of precipitates of the crystalline of (R) - (+) -verapamil hydrochloride from the solution, wherein the collected precipitate is the crystalline of (R) - (+) -verapamil hydrochloride, which has a powder X-ray diffraction pattern comprising either characteristic peaks of 8.5° ⁇ 0.1°, 9.5° ⁇ 0.1°, 17.6° ⁇ 0.1°, 21.4° ⁇ 0.1°, and 22.3° ⁇ 0.1°at reflection angles 2 ⁇ ; or characteristic peaks of 12.7° ⁇ 0.1°, 18.7° ⁇ 0.1°, 19.2° ⁇ 0.1°, 20.2° ⁇ 0.1°, and 21.2° ⁇ 0.1°at reflection angles 2 ⁇ .
- the dissolving step is performed at an elevated temperature that is between about 53°Cand 70°C.
- (R) - (+) -verapamil hydrochloride is dissolved at about 60°C.
- (R) - (+) -verapamil hydrochloride is dissolved at about 70°C.
- the cooling step is performed by cooling the solution to about room temperature. In other embodiments, the cooling step is performed by cooling the solution to about 4°C.
- the method of the present disclosure may further comprise a step of drying the precipitates.
- the method of the present disclosure may further comprise a step of heating the solvent.
- FIG 1 is a graph illustrating the powder X-ray diffractometry of the commercial available (R) - (+) -verapamil HCl in accordance with one embodiment of the present disclosure
- FIG 2 is a graph illustrating the powder X-ray diffractometry of the Form E crystal of (R) - (+) -verapamil HCl in accordance with one embodiment of the present disclosure
- FIG 3 is a graph illustrating the powder X-ray diffractometry of the Form T crystal of (R) - (+) -verapamil HCl in accordance with one embodiment of the present disclosure.
- FIG 4 is a graph illustrating the moisture sorption and desorption of the Form E crystal of (R) - (+) -verapamil HCl in accordance with one embodiment of the present disclosure.
- FIG 5 is a graph illustrating the moisture sorption and desorption of the Form T crystal of (R) - (+) -verapamil HCl in accordance with one embodiment of the present disclosure.
- the present disclosure is aimed to obtain the crystalline of (R) - (+) verapamil HCl by a crystallization process, which in general, involves dissolving (R) - (+) verapamil HCl in a solvent until saturation, and cooling the saturated solution to precipitate the desired crystal therefrom.
- the obtained crystal is then subject to X-ray diffraction crystallographic analysis.
- the crystals of the present disclosure respectively yield a characteristic powder X-ray diffraction pattern (XRD) , and each crystal has a specific value of 2 ⁇ .
- XRD X-ray diffraction pattern
- I max denotes the most intense peak in the powder X-ray diffraction chart measured in a powder sample of a crystal
- I denotes an intensity of each peak.
- the value of 2 ⁇ of the powder X-ray diffraction pattern can vary by approximately 0.1°to 0.5°with the state of the sample and measuring conditions. Because of properties of data of the powder X-ray diffraction pattern, general pattern is important for identifying the crystal form. Further, since a relative intensity can slightly vary with the growth direction of crystals, size of particles and/or measuring conditions, the intensity values in the XRD pattern should not be strictly interpreted.
- the main objective of the present disclosure is to provide novel crystalline forms of (R) - (+) verapamil HCl.
- solvent suitable for preparing novel crystalline forms of (R) - (+) verapamil HCl may be ethyl acetate, toluene, or a 1: 1 volumetric mixture of 1, 4-dioxane and heptane.
- a novel crystalline of (R) - (+) verapamil HCl is prepared from a saturated ethyl acetate (EtOAc) solution.
- EtOAc saturated ethyl acetate
- (R) - (+) verapamil HCl crystalizes from the saturated EtOAc solution is termed “form E crystal, ” which yields a powder X-ray diffraction pattern comprising characteristic peaks of 12.7° ⁇ 0.1°, 18.7° ⁇ 0.1°, 19.2° ⁇ 0.1°, 20.2° ⁇ 0.1°, and 21.2° ⁇ 0.1°at reflection angles 2 ⁇ .
- the powder X-ray diffraction pattern of the form E crystalline of (R) - (+) verapamil hydrochloride further comprises characteristic peaks of 6.4° ⁇ 0.1°, 8.3° ⁇ 0.1°, 10.7° ⁇ 0.1°, 15.5° ⁇ 0.1°, 15.9° ⁇ 0.1°, 17.5° ⁇ 0.1°, 20.4° ⁇ 0.1°, 23.9° ⁇ 0.1°, 24.4° ⁇ 0.1°, 25.4° ⁇ 0.1°, 25.9° ⁇ 0.1°, 27.7° ⁇ 0.1°, 27.0° ⁇ 0.1°, and 29.8° ⁇ 0.1°at reflection angles 2 ⁇ . Specifically, it yields a powder X-ray diffraction pattern as substantially depicted in FIG 2.
- Thermal analysis indicates a phase change occurred at an endothermic temperature from about 139 ⁇ 0.1°C.
- Hygroscopic analysis indicates the form E crystal may pick up 21%moisture at about 95%RH, as compared to about 30%of the non-crystalline form of verapamil hydrochloride.
- (R) - (+) verapamil HCl crystalizes from the saturated toluene solution is termed “form T crystal, ” which yields a powder X-ray diffraction pattern having characteristic peaks of a powder X-ray diffraction pattern comprising characteristic peaks of 8.5° ⁇ 0.1°, 9.5° ⁇ 0.1°, 17.6° ⁇ 0.1°, 21.4° ⁇ 0.1°, and 22.3° ⁇ 0.1°at reflection angles 2 ⁇ .
- the powder X-ray diffraction pattern of form T crystalline of (R) - (+) verapamil hydrochloride further comprises characteristic peaks of 5.4° ⁇ 0.1°, 9.6° ⁇ 0.1°, 15.7° ⁇ 0.1°, 17.1° ⁇ 0.1°, 21.5° ⁇ 0.1°, 21.6° ⁇ 0.1°, 23.3° ⁇ 0.1°, 24.6° ⁇ 0.1°and 25.5° ⁇ 0.1°at reflection angles 2 ⁇ . Specifically, it yields a powder X-ray diffraction pattern as substantially depicted in FIG 3.
- Thermal analysis indicates a phase change occurred at an endothermic temperature from about 132 ⁇ 0.1°C.
- Hygroscopic analysis indicates the form T crystal may pick up about 23%moisture at about 95%RH, as compared to about 30%of the non-crystalline form of verapamil hydrochloride.
- the impurity level of the crystal of the present disclosure is reduced after each cooling and crystallizing step.
- the individual impurity level of the crystal is less than 1.0%; more preferably, less than 0.5%; still more preferably, less than 0.1%.
- the crystalline of the present disclosure having an impurity level less than 1.0%means that the crystal has less than 1.0%of other non- (R) - (+) verapamil HCl compounds; the crystalline of the present disclosure having an impurity level less than 0.5%means that the crystal has less than 0.5%of other non- (R) - (+) verapamil HCl compounds; and the crystalline of the present disclosure having an impurity level less than 0.1%means that the crystal has less than 0.1%of other non- (R) - (+) verapamil compound.
- Any crystal thus obtained can be used as an active pharmaceutical ingredient of a medicine. Any of the crystal may be used alone or as a mixture of both forms.
- the use of form E or T crystalline of (R) - (+) verapamil HCl is advantageous for handling and storage stability as compared with the case of using no crystal.
- the form E or T crystalline of (R) - (+) -verapamil HCl is easily handled because of its crystal form, and the purification and drying effect is easily exerted; also, the crystal has improved storage stability and is useful as an active pharmaceutical ingredient of a medicine.
- each novel crystals of the present disclosure is useful as a medicament for treating diseases or conditions related to orexin receptors 1 and 2, somatostatin receptor 2, dopamine D 2L receptor, sodium channel, or L-type and N-type calcium channels.
- Examples for the diseases or conditions related to orexin receptors 1 and 2 include, but are not limited to, obesity, migraine, cluster headache, narcolepsy, Parkinson's disease, Alzheimer’s disease, depression, addictions, anxiety, cancer, diabetes, insomnia, irritable bowel syndrome, neuropathic pain, pain, schizophrenia, sleep disorder, and Tourette syndrome.
- Examples for the disease or condition related to somatostatin receptor 2 include, but are not limited to, Crushing’s syndrome, gonadotropinoma, gastrinoma, Zollinger-Ellison syndrome, hypersecretory diarrhea related to AIDS and other conditions, irritable bowel syndrome, pancreatitis, Crohn’s disease, systemic sclerosis, thyroid cancer, psoriasis, hypotension, panic attacks, scleroderma, small bowel obstruction, gastroesophageal reflux, duodenogastric reflux, Grave’s disease, polycystic ovary disease, upper gastrointestinal bleeding, pancreatic pseudocyst, pancreatic ascites, leukemia, meningioma, cancer cachexia, acromegaly, restenosis, hepatoma, lung cancer, melanoma, wasting, type 2 diabetes, Syndrome X, fibrosis, hyperlipidemia, hyperamylinemia, hyperprolactinemia, prolactinomas, cluster
- Examples for the disease or condition related to dopamine D 2L receptor include, but are not limited to, schizophrenia, anxiety, depression, migraine, pain, Parkinson's disease, addiction and Tourette syndrome.
- Examples for the disease or condition related to sodium channel include, but are not limited to, atrial fibrillation, ventricular fibrillation, long QT syndrome, and hyperkalaemic periodic paralysis.
- Examples for the disease or condition related to L-and N-type calcium channels include, but are not limited to, hypokalaemic periodic paralysis, episodic ataxia type 2, and familia hemiplegic migraine.
- each crystal of (R) - (+) verapamil HCl or a solvent thereof of the present disclosure may constitute pharmaceutical compositions with pharmaceutical acceptable carriers, and can be administered to a subject orally or parenterally in various dosage forms.
- Parenteral administration includes, for example, administration by intraveneous, subcutaneous, intramuscular, transdermal, intrarectal, transnasal, and instillation methods.
- the dosage form of the pharmaceutical composition for oral administration includes, for example, tablets, pills, granules, powders, solutions, suspensions, syrups or capsules.
- a method of producing a tablet, a pill, granule or powder it can be formed by conventional techniques using a pharmaceutically acceptable carrier such as excipient, binder, or disintegrant and etc.
- a solution, suspension or syrup it can be produced by conventional techniques using glycerol esters, alcohols, water or vegetable oils, and etc.
- the form of capsule can be produced by filling a capsule made of gelatin with the granule, powder or a solution prepared as described above.
- an injection can be prepared by dissolving the crystalline of the present disclosure in water soluble solution such as physiological saline, or water insoluble solution consisting of organic esters such as propylene glycol, polyethylene glycol, or vegetable oils (e.g., sesame oil) .
- a dosage form as an ointment or a cream can be employed.
- the ointment can be produced by mixing the crystal of the present disclosure with fats or oils and etc; and the cream can be produced by mixing the crystal of the present disclosure with emulsifiers.
- rectal administration it may be in the form of suppository using a gelatin soft capsule.
- transdermal administration it may be in a form of a liquid or a powdery formulation.
- a liquid formulation water, salt solution, phosphate buffer, acetate buffer and etc may be used as a base; it may also contain surfactants, antioxidants, stabilizers, preservatives or tackifiers.
- a powdery formulation it may contain water-absorbing materials such as water-soluble polyacrylates, cellulose low-alkyl esters, polyethylene glycol polyvinyl pyrrolidone, amylase and etc, and non-water absorbing materials such as cellulose, starches, gums, vegetable oils or cross-linked polymers.
- antioxidants, colorants, preservatives may be added to the powdery formulation.
- the liquid or powdery formulation may be administered by use of a spray apparatus.
- a solution or suspension containing the crystal of the present disclosure and a pharmaceutical excipient generally accepted for this purpose is inhaled through an inhalant aerosol spray.
- the crystal of the present disclosure in the form of a powder may be administered through inhalator that allows direct contact of the powder with the lung.
- pharmaceutical acceptable carriers such as isotonic agents, preservatives, dispersions, or stabilizers may be added. Further, if necessary, these formulations may be sterilized by filtration, or by treatment with heat or irradiation.
- the pharmaceutical composition or medicament comprising an effective amount of the crystalline of the present disclosure is suitable for treating diseases or conditions related to orexin receptors 1 and 2, somatostatin receptor 2, dopamine D 2L receptor, sodium channel, and L-and N-type calcium channels, such as obesity, migraine, cluster headache, narcolepsy, Parkinson's disease, Alzheimer’s disease, depression, addictions, anxiety, cancer, diabetes, insomnia, irritable bowel syndrome, neuropathic pain, pain, schizophrenia, sleep disorder, Tourette syndrome, Crushing’s syndrome, gonadotropinoma, gastrinoma, Zollinger-Ellison syndrome, hypersecretory diarrhea related to AIDS and other conditions, pancreatitis, Crohn’s disease, systemic sclerosis, psoriasis, hypotension, panic attacks, scleroderma, small bowel obstruction, gastroesophageal reflux, duodenogastric reflux, Grave’s disease, polycystic ovary disease, upper gastrointestinal bleeding, pancreatic pseudocy
- the effective amount of the crystal of the present disclosure suitable for treating any of the afore-mentioned conditions varies with the route of administration, or condition, age, sex, or weight of the subject receiving the treatment.
- the crystal of the present disclosure is administered to the subject at least once a week, such as 1, 2, or 3 times per week.
- the effective amount is about 10-2,000 mg/week, preferably about 20-1,800 mg/week in the case of oral administration; whereas it is about 1-1, 000 mg/week, preferably about 5-500 mg/week in the case of intravenous, intramuscular, subcutaneous, transdermal, transnasal, intrarectal, or inhalation.
- Crystallization was carried out by slow and/or fast cooling from a hot saturated solution.
- about 30 mg (R) - (+) -verapamil HCl was dissolved in the least volume of indicated solvents, including those listed in the following Table 1, and others, such as N,N-dimethylacetamide, acetic acid, and etc, at 53-70°Cuntil all powders were completely dissolved.
- the vial was left to cool down to room temperature (about 25°C) ; as to fast cooling, the vial was immediately placed in an iced bath to cool to about 4°C. Both solutions, either in the fast or slow cooling, were let stand for no more than 3 days.
- the crystal was subject to differential scanning calorimetry (DSC) analysis over the range of 30°C/300°Cwith a gradient of 10°C/min under nitrogen purge, and the presence or absence of endotherm peaks was observed.
- DSC differential scanning calorimetry
- the crystal was also subject to thermogravimetric (TGA) analysis over the range of 30°C/350°Cwith a gradient of 10°C/min under nitrogen purge; and weight loss, decomposition, and phase transition of the crystal were observed.
- TGA thermogravimetric
- the melting point of the crystal was determined using a capillary method (e.g., Thomas-Hoover or the Mel-Temp apparatus) .
- a capillary method e.g., Thomas-Hoover or the Mel-Temp apparatus.
- the capillary which contained the sample, and a thermometer were then suspended so that they were heated slowly and evenly. The temperature range over which the sample was observed to melt was taken as the melting point.
- X-ray Powder Diffractometry X-ray Powder Diffractometry. X-ray diffraction patterns were obtained on D2 phaser X-ray diffractometer system (Bruker AXS Gmbh, Germany) . Samples were scanned in continuous mode from 5-50° (2 ⁇ ) with step size of 5 ⁇ /min on a spinning stage at 30 kV and 10 mA with Cu K ⁇ radiation ( ) . The incident beam path was equipped with a 1mm divergence slit and 1mm air scattering screen. The diffracted beam was equipped with Ni-filter. Detection was accomplished with a Lynxeye (2.5) detector (Bruker AXS) .
- Hygroscopicity was determined by dynamic vapor sorption (DVS) performed on the DVS Advantage (Surface Measurement Systems Ltd., London) DVS is a technique that measures how quickly and how much of a solvent (e.g., water or an organic solvent) being absorbed by a sample. Measurements were taken from 0 to 95%RH at 25°Cwith 5%RH per step with equilibration set to dm/dt+0.002%/min for 5 min or 120 min/step. All samples reached equilibration at each step before the 120 min maximum set point was reached.
- a solvent e.g., water or an organic solvent
- Crystal samples were placed in an environment of (a) 40°C/75%RH, open vial; (b) 50°C, airtight container; and (c) 4,500 LUX, respectively, for 1, 7 and 21 days, and thereafter subjected to high performance liquid chromatography (HPLC) to determine the level of impurity.
- HPLC high performance liquid chromatography
- ACN Acetonitrile
- DCM Dichloromethane
- DMF dimethylformamide
- DMSO dimethyl sulfoxide
- EG ethylene glycol
- MetOH methanol
- IPA isopropanol
- EtOAc ethyl acetate
- MEK methyl ethyl ketone
- THF tetrahydrofuran.
- (R) - (+) -verapamil HCl was found to be quite soluble in water, acetone, DMSO, MEK, ACN, n-propanol, 1, 4-dioxane, ethylene glycol, H 2 O/IPA (1: 1) , H 2 O/THF (1: 1) , H 2 O/acetone (1: 1) , EtOH/DCM (1: 1) , EtOH/heptane (1: 1) , and toluene/MetOH (1: 1) ; soluble in DCM, DMF, IPA, THF, EtOH/MEK (1: 1) , 1-butanol; soluble to just a minor extent in EtOAc, toluene, 1, 4-dioxane/heptane (1: 1) ; and insoluble in heptane.
- EtOAc, toluene, and 1, 4-dioxane/heptane (1: 1) were chosen as the solvents for subsequent crystallization.
- the crystal was subject to X-ray diffraction (XRD) and thermal analysis, and was termed “form E. ”
- FIG 2 illustrates the X-ray diffraction pattern of form E crystal, in which major diffraction peaks were observed at approximately 12.7° ⁇ 0.1°, 18.7° ⁇ 0.1°, 19.2° ⁇ 0.1°, 20.2° ⁇ 0.1°, and 21.2° ⁇ 0.1°at reflection angles 2 ⁇ ; minor diffraction peaks were observed at approximately 6.4° ⁇ 0.1°, 8.3° ⁇ 0.1°, 10.7° ⁇ 0.1°, 15.5° ⁇ 0.1°, 15.9° ⁇ 0.1°, 17.5° ⁇ 0.1°, 20.4° ⁇ 0.1°, 23.9° ⁇ 0.1°, 24.4° ⁇ 0.1°, 25.4° ⁇ 0.1°, 25.9° ⁇ 0.1°, 27.0° ⁇ 0.1°, 27.7° ⁇ 0.1°, and 29.8° ⁇ 0.1°at reflection angles 2 ⁇ .
- the crystal was subject to X-ray diffraction (XRD) and thermal analysis, and was termed “form T. ”
- FIG 3 illustrates the X-ray diffraction pattern of form T crystal, in which major diffraction peaks were observed at approximately 8.5° ⁇ 0.1°, 9.5° ⁇ 0.1°, 17.6° ⁇ 0.1°, 21.4° ⁇ 0.1°, and 22.3° ⁇ 0.1°at reflection angles 2 ⁇ ; and minor diffraction peaks were observed at approximately 5.4° ⁇ 0.1°, 9.6° ⁇ 0.1°, 15.7° ⁇ 0.1°, 17.1° ⁇ 0.1°, 21.5° ⁇ 0.1°, 21.6° ⁇ 0.1°, 23.3° ⁇ 0.1°, 24.6° ⁇ 0.1°and 25.5° ⁇ 0.1°at reflection angles 2 ⁇ .
- Example 2 Characterization of the Crystals of Example 1.2 and 1.3
- Example 1.2 The form E crystal of Example 1.2 and form T crystal of example 1.3 were respectively subject to hygroscopicity analysis in accordance with procedures described in “Materials and Methods” section.
- Example 1.2 The form E crystal of Example 1.2 and form T crystal of example 1.3 were respectively placed in containers and stored in the designated conditions as described in the “Materials and Methods” section, and thereafter subjected to HPLC analysis to determine the level of impurity. Results are summarized in Table 2.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (20)
- A form E crystalline of (R) - (+) -verapamil hydrochloride comprising a powder X-ray diffraction pattern comprising characteristic peaks of 12.7°±0.1°, 18.7°±0.1°, 19.2°±0.1°, 20.2°±0.1°, and 21.2°±0.1°at reflection angles 2θ.
- The form E crystalline of (R) - (+) -verapamil hydrochloride of claim 1, further comprising characteristic peaks of 6.4°±0.1°, 8.3°±0.1°, 10.7°±0.1°, 15.5°±0.1°, 15.9°±0.1°, 17.5°±0.1°, 20.4°±0.1°, 23.9°±0.1°, 24.4°±0.1°, 25.4°±0.1°, 25.9°±0.1°, 27.0°±0.1°, 27.7°±0.1°, and 29.8°±0.1°at reflection angles 2θ.
- The form E crystalline of (R) - (+) -verapamil hydrochloride of claim 2, wherein the powder X-ray diffraction pattern is substantially as depicted in FIG 2.
- The form E crystalline of (R) - (+) -verapamil hydrochloride of claim 1, wherein, as measured by differential scanning calorimetry (DSC) , the form E crystalline has an endothermic peak at about 139 ± 0.1 ℃.
- The form E crystalline of (R) - (+) -verapamil hydrochloride of claim 1, wherein the crystal has a water content of 0% (wt%) at 3%RH, and about 21%(wt%) at 95%RH.
- A form T crystalline of (R) - (+) -verapamil hydrochloride comprising a powder X-ray diffraction pattern comprising characteristic peaks of 8.5°±0.1°, 9.5°±0.1°, 17.6°±0.1°, 21.4°±0.1°, and 22.3°± 0.1°at reflection angles 2θ.
- The form T crystalline of (R) - (+) -verapamil hydrochloride of claim 6, further comprising characteristic peaks of 5.4°±0.1°, 9.6°±0.1°, 15.7°±0.1°, 17.1°±0.1°, 21.5°±0.1°, 21.6°±0.1°, 23.3°±0.1°, 24.6°±0.1° and 25.5°± 0.1°at reflection angles 2θ.
- The form T crystalline of (R) - (+) -verapamil hydrochloride of claim 7, wherein the powder X-ray diffraction pattern is substantially as depicted in FIG 3.
- The form T crystalline of (R) - (+) -verapamil hydrochloride of claim 6, wherein, as measured by DSC, the form T crystalline has an endothermic peak at about 132 ± 0.1 ℃.
- The form T crystalline of (R) - (+) -verapamil hydrochloride of claim 6, wherein the crystal has a water content of about 0% (wt%) at 3%RH, and about 23%(wt%) at 95%RH.
- A method of making a crystalline of (R) - (+) -verapamil hydrochloride comprising:dissolving (R) - (+) -verapamil hydrochloride in the least amount of a solvent to form a solution;cooling the solution; andcollecting an amount of precipitates of the crystalline of (R) - (+) -verapamil hydrochloride from the solution,wherein,the collected precipitate is the crystalline of (R) - (+) -verapamil hydrochloride, which has a powder X-ray diffraction pattern comprising either characteristic peaks of 8.5°±0.1°, 9.5°±0.1°, 17.6°±0.1°, 21.4°±0.1°, and 22.3°±0.1° at reflection angles 2θ; or characteristic peaks of 12.7°±0.1°, 18.7°±0.1°, 19.2°±0.1°, 20.2°±0.1°, and 21.2°±0.1° at reflection angles 2θ.
- The method of claim 11 wherein the solvent is selected from the group consisting of ethyl acetate, 1, 4-dioxane/heptane (1: 1 by volume) , toluene, dimethylformamide, N, N-dimethylacetamide, acetic acid, methanol, and ethylene glycol.
- The method of claim 11, further comprising a step of heating the solvent to about 53-60 ℃, wherein the solvent is EtOAc.
- The method of claim 13, wherein the powder X-ray diffraction pattern further comprises characteristic peaks of 6.4°±0.1°, 8.3°±0.1°, 10.7°±0.1°, 15.5°±0.1°, 15.9°±0.1°, 17.5°±0.1°, 20.4°±0.1°, 23.9°±0.1°, 24.4°±0.1°, 25.4°±0.1°, 25.9°±0.1°, 27.0°±0.1°, 27.7°±0.1°, and 29.8°±0.1°at reflection angles 2θ.
- The method of claim 14, wherein the powder X-ray diffraction pattern is substantially as depicted in FIG 2.
- The method of claim 15, wherein, as measured by differential scanning calorimetry (DSC) , the crystalline of (R) - (+) -verapamil hydrochloride has an endothermic peak at about 139 ± 0.1 ℃.
- The method of claim 11, further comprising a step of heating the solvent to about 70 ℃, wherein the solvent is toluene.
- The method of claim 17, wherein the powder X-ray diffraction pattern further comprises characteristic peaks of 5.4°±0.1°, 9.6°±0.1°, 15.7°±0.1°, 17.1°±0.1°, 21.5°±0.1°, 21.6°±0.1°, 23.3°±0.1°, 24.6°±0.1° and 25.5°±0.1° at reflection angles 2θ.
- The method of claim 18, wherein the powder X-ray diffraction pattern is substantially as depicted in FIG 3.
- The method of claim 18, wherein, as measured by differential scanning calorimetry (DSC) , the crystalline of (R) - (+) -verapamil hydrochloride has an endothermic peak at about 132 ± 0.1 ℃.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201580058236.3A CN107108477A (en) | 2014-10-29 | 2015-07-13 | Verapamil hydrochloride crystal type |
CA2964177A CA2964177A1 (en) | 2014-10-29 | 2015-07-13 | Crystal forms of verapamil hydrochloride |
US15/521,304 US9950995B2 (en) | 2014-10-29 | 2015-07-13 | Crystal forms of verapamil hydrochloride |
JP2017522983A JP2017533911A (en) | 2014-10-29 | 2015-07-13 | Crystal form of verapamil hydrochloride |
AU2015341341A AU2015341341A1 (en) | 2014-10-29 | 2015-07-13 | Crystal forms of verapamil hydrochloride |
EP15856106.8A EP3212611A4 (en) | 2014-10-29 | 2015-07-13 | Crystal forms of verapamil hydrochloride |
TW104125070A TWI564280B (en) | 2014-10-29 | 2015-08-03 | Crystal forms of verapamil hydrochloride |
US15/917,817 US10144704B2 (en) | 2014-10-29 | 2018-03-11 | Crystal forms of verapamil hydrochloride |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462072172P | 2014-10-29 | 2014-10-29 | |
US62/072,172 | 2014-10-29 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/521,304 A-371-Of-International US9950995B2 (en) | 2014-10-29 | 2015-07-13 | Crystal forms of verapamil hydrochloride |
US15/917,817 Division US10144704B2 (en) | 2014-10-29 | 2018-03-11 | Crystal forms of verapamil hydrochloride |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016065930A1 true WO2016065930A1 (en) | 2016-05-06 |
Family
ID=55856541
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2015/083854 WO2016065930A1 (en) | 2014-10-29 | 2015-07-13 | Crystal forms of verapamil hydrochloride |
Country Status (8)
Country | Link |
---|---|
US (2) | US9950995B2 (en) |
EP (1) | EP3212611A4 (en) |
JP (1) | JP2017533911A (en) |
CN (1) | CN107108477A (en) |
AU (1) | AU2015341341A1 (en) |
CA (1) | CA2964177A1 (en) |
TW (1) | TWI564280B (en) |
WO (1) | WO2016065930A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108430467A (en) * | 2016-05-20 | 2018-08-21 | 晟德大药厂股份有限公司 | The method for treating hyperglycemia |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3915562A1 (en) | 2020-05-31 | 2021-12-01 | Genovate Biotechnology Co., Ltd. | Treatment of lupus erythematosus using s- hydroxychloroquine |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101012185B (en) * | 2007-02-16 | 2011-04-27 | 天津市中央药业有限公司 | Method of refining verapamil hydrochloride |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2008A (en) * | 1841-03-18 | Gas-lamp eok conducting gas pkom ah elevated buhner to one below it | ||
JPS5392732A (en) * | 1977-01-27 | 1978-08-15 | Teikoku Hormone Mfg Co Ltd | Novel process for preparation of nitrile derivatives |
ATE32061T1 (en) * | 1984-06-15 | 1988-02-15 | Heumann Ludwig & Co Gmbh | PROCESS FOR THE PRODUCTION OF BASIC SUBSTITUTED PHENYLACETONITRILES. |
DE3723684A1 (en) * | 1987-07-17 | 1989-01-26 | Basf Ag | Process for the preparation of the enantiomers of verapamil |
PL162512B1 (en) * | 1990-03-27 | 1993-12-31 | Pabianickie Zaklad Farma | Method of isolating alpha- isopropyl -alpha-]/n-methyl-n-homoveratril/-gamma-aminopropyl¦-3,4-dimethoxyphenylacetonitrile hydrochloride |
DE4203547A1 (en) * | 1992-02-07 | 1993-08-12 | Knoll Ag | METHOD FOR RACEMAT SEPARATION OF VERAPAMIL |
CN1087725C (en) * | 1994-03-25 | 2002-07-17 | 同位素技术有限公司 | Enhancement of the effect of drugs by deuteration |
JP2000504683A (en) * | 1996-02-08 | 2000-04-18 | ダーウィン・ディスカバリー・リミテッド | Resolution of 4-cyano-4- (3,4-dimethoxyphenyl) -5-methylhexanoic acid |
US5859279A (en) * | 1996-09-10 | 1999-01-12 | Darwin Discovery Limited | Compound and process |
GB9618835D0 (en) * | 1996-09-10 | 1996-10-23 | Chiroscience Ltd | Process |
-
2015
- 2015-07-13 CA CA2964177A patent/CA2964177A1/en not_active Abandoned
- 2015-07-13 JP JP2017522983A patent/JP2017533911A/en active Pending
- 2015-07-13 WO PCT/CN2015/083854 patent/WO2016065930A1/en active Application Filing
- 2015-07-13 EP EP15856106.8A patent/EP3212611A4/en not_active Withdrawn
- 2015-07-13 CN CN201580058236.3A patent/CN107108477A/en active Pending
- 2015-07-13 US US15/521,304 patent/US9950995B2/en active Active
- 2015-07-13 AU AU2015341341A patent/AU2015341341A1/en not_active Abandoned
- 2015-08-03 TW TW104125070A patent/TWI564280B/en not_active IP Right Cessation
-
2018
- 2018-03-11 US US15/917,817 patent/US10144704B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101012185B (en) * | 2007-02-16 | 2011-04-27 | 天津市中央药业有限公司 | Method of refining verapamil hydrochloride |
Non-Patent Citations (2)
Title |
---|
See also references of EP3212611A4 * |
YANG YULONG ET AL.: "The Optic Resolution of (±)-Verapamil", CHINESE JOURNAL OF MEDICINAL CHEMISTRY, vol. 10, no. 3, 20 September 2000 (2000-09-20), pages 207 - 208, XP009502667 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108430467A (en) * | 2016-05-20 | 2018-08-21 | 晟德大药厂股份有限公司 | The method for treating hyperglycemia |
EP3413886A4 (en) * | 2016-05-20 | 2019-09-18 | Center Laboratories, Inc. | Method of treating hyperglycemia |
RU2739255C2 (en) * | 2016-05-20 | 2020-12-22 | Сентер Лабораториз, Инк. | Method of treating hyperglycaemia |
CN108430467B (en) * | 2016-05-20 | 2021-06-22 | 晟德大药厂股份有限公司 | Use of (R) - (+) -verapamil for the treatment of hyperglycemia and pharmaceutical compositions thereof |
KR20210121305A (en) * | 2016-05-20 | 2021-10-07 | 센터 래버러토리스 아이엔씨 | Method of treating hyperglycemia |
KR102423967B1 (en) | 2016-05-20 | 2022-07-21 | 센터 래버러토리스 아이엔씨 | Method of treating hyperglycemia |
IL262994B1 (en) * | 2016-05-20 | 2023-03-01 | Center Laboratories Inc | Method of treating hyperglycemia |
IL262994B2 (en) * | 2016-05-20 | 2023-07-01 | Center Laboratories Inc | Method of treating hyperglycemia |
Also Published As
Publication number | Publication date |
---|---|
US9950995B2 (en) | 2018-04-24 |
TW201702216A (en) | 2017-01-16 |
EP3212611A4 (en) | 2018-05-30 |
TWI564280B (en) | 2017-01-01 |
US20170305841A1 (en) | 2017-10-26 |
US20180194719A1 (en) | 2018-07-12 |
CN107108477A (en) | 2017-08-29 |
AU2015341341A1 (en) | 2017-04-27 |
CA2964177A1 (en) | 2016-05-06 |
JP2017533911A (en) | 2017-11-16 |
EP3212611A1 (en) | 2017-09-06 |
US10144704B2 (en) | 2018-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6028016B2 (en) | Polymorphs of linagliptin benzoate | |
JP5543982B2 (en) | Tosylate salt of 5-pyrazolyl-2-pyridone derivative useful for the treatment of COPD | |
CN109311832B (en) | Pamoic acid salt of vortioxetine and crystal forms thereof | |
CA2984724C (en) | Crystal of uracil compound | |
WO2011095059A1 (en) | Polymorphs of dasatinib, preparation methods and pharmaceutical compositions thereof | |
US7977348B2 (en) | Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α | |
JP2022137223A (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
JP2008501024A (en) | Mixed co-crystal and pharmaceutical composition comprising the same | |
US10144704B2 (en) | Crystal forms of verapamil hydrochloride | |
EP2651952A2 (en) | Polymorphic forms of asenapine maleate and processes for their preparation | |
JP2016512518A (en) | Solid form of Vemurafenib hydrochloride | |
JP2018516912A (en) | Improved method of manufacturing apremilast and its novel polymorph | |
EP3042893B1 (en) | Novel crystalline arylalkylamine compound and method for producing same | |
US10464946B2 (en) | Crystalline forms of thienopyrimidine compound | |
CN104341343B (en) | Crystal form of betrixaban and its preparation method and application | |
CA2940902A1 (en) | Polymorphs and solid states of tiacumicin b | |
US10206916B2 (en) | Cabozantinib salts and their use as anti-cancer agents | |
US20210015817A1 (en) | Solid-state forms of abemaciclib, their use and preparation | |
US9464086B2 (en) | Crystalline forms of N,N-dicyclopropyl-4-(1,5-dimethyl-1 H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-D]pyrrolo[2,3-B]pyridine-7-carboxamide for the treatment of myeloproliferative disorders | |
JP5872105B2 (en) | Pyrrolidin-3-ylacetic acid derivative salt and crystal thereof | |
EP2886543A1 (en) | Crystalline form of mastinib mesylate | |
EP3170819B1 (en) | Novel crystalline form of 5-chloro-n-({(5s)-2-oxo-3-[4-(5,6-dihydro-4h-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and pharmaceutical composition containing same | |
EP4137133A1 (en) | Crystalline form of avacopan | |
US9381199B2 (en) | Linagliptin solid dispersion | |
KR20100101405A (en) | Method of preparing non-crystalline (+)-lansoprazole and (+)-lansoprazole alcoholate used therein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15856106 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2964177 Country of ref document: CA |
|
REEP | Request for entry into the european phase |
Ref document number: 2015856106 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017522983 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15521304 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2015341341 Country of ref document: AU Date of ref document: 20150713 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |